Gene Therapy to Target CD19 for Leukemia or Lymphoma is under clinical development by Xi’An Yufan Biotechnology and currently in Phase I for Hairy Cell Leukemia. According to GlobalData, Phase I drugs for Hairy Cell Leukemia have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Target CD19 for Leukemia or Lymphoma’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy to Target CD19 for Leukemia or Lymphoma overview
Gene therapy is under development for the treatment of acute lymphocytic leukemia, chronic lymphocytic leukemia (CLL), follicular lymphoma, marginal zone b-cell lymphoma, Waldenstrom macroglobulinemia, hairy cell leukemia, diffuse large B-Cell lymphoma, Burkitt lymphoma, mantle cell lymphoma. It is administered by intravenous route. The therapeutic candidate comprises of autologous T-cells genetically transduced with a lentiviral vector to express chimeric antigen receptors (CAR) targeting cells expressing CD19. The CAR-T cells are electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1.
For a complete picture of Gene Therapy to Target CD19 for Leukemia or Lymphoma’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
